UPDATED Jun 24, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$904.61 | 1.5% | 94.7% | US$801.5b | US$860.55 | PE132.7x | E27.3% | 0.6% | Pharmaceuticals & Biotech | ||
UNH | US$484.50 | 0.7% | 0.4% | US$451.0b | US$575.77 | PE29x | E19.7% | 1.7% | Healthcare | ||
JNJ | US$147.19 | 1.1% | -9.9% | US$358.9b | US$171.72 | PE20.7x | S4.5% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$132.92 | 3.9% | 17.3% | US$336.8b | US$142.68 | PE146x | E23.7% | 2.3% | Pharmaceuticals & Biotech | ||
ABBV | US$170.75 | -0.4% | 28.8% | US$305.0b | US$183.24 | PE50.7x | E21.9% | 3.6% | Pharmaceuticals & Biotech | ||
AZN | UK£124.78 | 0.5% | 11.5% | UK£193.4b | UK£136.65 | PE38.8x | E14.7% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$556.52 | -2.2% | 9.2% | US$216.0b | US$629.39 | PE35.2x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
DHR | US$254.14 | -1.3% | 8.7% | US$190.2b | US$273.31 | PE46.3x | E13.7% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$105.49 | 1.4% | -2.1% | US$183.2b | US$125.16 | PE32.7x | E11.3% | 2.1% | Healthcare | ||
AMGN | US$319.31 | 4.4% | 43.4% | US$170.7b | US$316.44 | PE45.5x | E18.2% | 2.8% | Pharmaceuticals & Biotech | ||
PFE | US$27.99 | 2.1% | -23.1% | US$160.7b | US$31.92 | PS2.9x | E30.6% | 6.0% | Pharmaceuticals & Biotech | ||
ISRG | US$442.31 | 1.7% | 34.0% | US$152.2b | US$426.49 | PE78.9x | E11.7% | n/a | Healthcare | ||
SYK | US$339.55 | -2.6% | 13.7% | US$129.2b | US$372.94 | PE38.5x | E10.5% | 0.9% | Healthcare | ||
ELV | US$535.29 | 1.5% | 20.4% | US$125.9b | US$608.98 | PE19.9x | E12.1% | 1.2% | Healthcare | ||
VRTX | US$473.82 | 1.4% | 36.5% | US$122.6b | US$465.53 | PE30.4x | E10.4% | n/a | Pharmaceuticals & Biotech | ||
REGN | US$1,071.19 | 3.1% | 49.6% | US$114.8b | US$1,051.47 | PE30x | E12.3% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$77.51 | 1.6% | 44.9% | US$112.8b | US$82.35 | PE64.6x | E18.1% | n/a | Healthcare | ||
MDT | US$80.41 | 0.8% | -7.7% | US$103.9b | US$94.03 | PE28x | E12.8% | 3.5% | Healthcare | ||
CI | US$338.80 | 1.2% | 22.8% | US$97.5b | US$392.38 | PE26.6x | E18.1% | 1.7% | Healthcare | ||
CSL | AU$293.70 | -0.06% | 5.3% | AU$141.9b | AU$307.57 | PE38.2x | E14.7% | 1.2% | Pharmaceuticals & Biotech | ||
HCA | US$340.45 | -0.06% | 14.4% | US$89.4b | US$351.29 | PE16.3x | E6.0% | 0.8% | Healthcare | ||
GILD | US$69.61 | 10.2% | -8.4% | US$88.1b | US$82.97 | PE178.8x | E36.2% | 4.4% | Pharmaceuticals & Biotech | ||
BMY | US$42.19 | 3.4% | -34.8% | US$85.6b | US$53.19 | PS1.9x | E44.7% | 5.7% | Pharmaceuticals & Biotech | ||
GSK | UK£16.09 | -0.2% | 14.7% | UK£65.6b | UK£20.36 | PE14.6x | E12.4% | 3.6% | Pharmaceuticals & Biotech |